Zhao, Hong
3 papers on CoChatORCID 0000-0003-0323-5190
Most cited papers
- Verified
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 545
- Verified
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 469
- Verified
Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX -Mutant Cancers to WEE1 Inhibition
Liang, J., Zhao, H., Diplas, B. H., Liu, S., Liu, J., Wang, D., Lu, Y., Zhu, Q., Wu, J., Wang, W., et al. (2020) · Cancer Research
DNA Repair MechanismsChromatin Remodeling and Cancer
Cited by 75
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free